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Abstract
Background: Obesity in pregnancy is associated with systemic inflammation, immunological changes and adverse
maternal-fetal outcomes. Information on the association between maternal obesity and breast milk composition is
scarce. This study describes changes and relationships between biochemical and immunological parameters of
colostrum and serum of overweight and obese women.
Methods: Colostrum and blood samples were collected from 25 normal weight, 24 overweight and 19 obese
women for determination of glucose, total protein, triglycerides, cholesterol, immunoglobulins, complement
proteins (C3 and C4), fat and calorie content and C-reactive protein (CRP).
Results: Glucose was higher in colostrum of obese women (p = .002). In normal weight and obese women, total
protein content was higher in colostrum than in serum (p = .001). Serum triglycerides (p = .008) and cholesterol (p = .010)
concentrations were significantly higher in overweight and obese women than in their normal weight counterparts,
but in colostrum their concentrations were similar across the three groups. Secretory IgA (sIgA) in colostrum and IgA
in serum concentrations were significantly higher (p = .001) in overweight and obese mothers, whereas IgG and IgM
concentrations did not vary among the groups (p = .825). Serum C3 (p = .001) and C4 (p = .040) concentrations were
higher in obese women. No differences in colostrum complement proteins were detected among the groups. Calorie
content (p = .003) and fat (p = .005) concentrations in colostrum and serum CRP (p = .002) were higher in obese women.
Conclusions: The results corroborate the hypothesis that colostrum of overweight and obese women undergoes
biochemical and immunological changes that affect its composition, namely increasing glucose concentrations,
calorie content, fat and sIgA concentrations.
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Background
Breastfeeding promotion is one of the main strategies
for reducing child mortality worldwide [1]. Breast milk
contains a balanced content of macro and micronutrients
that are essential for infant growth and development, and
several immunological components that provide protection
to newborns [2–4]. Antibodies, complement proteins,
hormones, immunocompetent cells [3, 5–9] cytokines
[10–12] and other milk components appear to play a role
in the modulation and development of the immune
system and inflammatory responses of newborns.
In recent decades, due to changes in lifestyle the incidence
of overweight and obesity are increasing among breast-
feeding mothers. Obesity and overweight are common
metabolic disorders and their growing frequencies
worldwide are a major public health concern [13]. Obesity
has been shown to increase the expression and secretion
of proinflammatory cytokines such as tumor necrosis
alpha factor (TNF-α) and interleukin 6 (IL-6) and raises
plasma C-reactive protein (CRP) concentrations, leading
to the chronic low-grade inflammation that characterizes
the disease [14] and appears to play a central role in the
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development of a variety of metabolic disorders and
hormonal dysfunctions [15–17]. The fact that obesity
affects components of the cellular and humoral immune
response may result in a state of immunodeficiency [18].
Epidemiological and clinical findings corroborate this,
showing a higher incidence and severity of infectious
diseases in the obese [19].
The risks associated with obesity become even more rele-
vant in women of reproductive age [20, 21] because preg-
nancy is another condition that affects immune response.
Moreover, excess weight during pregnancy contributes to
increasing perinatal morbidity and mortality, posing risks of
long-term consequences for mother and child [22].
Other studies show that chronic inflammation caused
by obesity may be related to an exaggerated inflammatory
response in the placenta of pregnant women, with an accu-
mulation of macrophages and pro-inflammatory mediators
[23]. However, it is unclear whether the effects of obesity
in pregnancy are accompanied by changes in colostrum
composition in the post partum period.
Changes in maternal metabolism and immunological
response may affect the developing immune system of
newborns because of the intense interplay between mother
and child during pregnancy and breastfeeding. To clarify
this issue, the present study investigated the association
between maternal weight and immunological, biochemical
and nutritional parameters of colostrum.
Methods
This cross-sectional study evaluated 68 mothers (18–36
years of age), divided into three groups according to
their prepregnancy body mass index (BMI): normal
weight (n = 25); overweight (n = 24) and obese (n = 19).
Group definition was based on the World Health
Organization [24] criterion, considering normal weight for
BMI 18.5–24.9, overweight for BMI 25–29.9, and obesity
for BMI of 30 or more. Participants were recruited from
the Pregnancy and Obstetric Service of the Maria José dos
Santos Stein Hospital, managed by the School of Medicine
of ABC, Santo André, SP, Brazil. The volunteers signed an
informed consent form before entering the study, which
was approved by the local ethics committee of the Faculty
of Public Health of the University of São Paulo (Protocol
Number CAAE: 05269612.7.0000.5421).
A number of variables were controlled in both groups.
These patients were characterized by the age, gestational
age at delivery, smoking status, hypertension, body mass
indexes before pregnancy, diabetes prior to pregnancy
and gestational diabetes.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (a) women with
breasts without nipple fissures or mastitis; (b) who were
exclusively breastfeeding their babies; and (c) signed a
Consent Form. Women with multiple pregnancies, fetal
malformations and deliveries before the 37th week of
gestation were excluded.
Colostrum sampling
About 48–72 h post-partum, 10 mL colostrum was
collected from the volunteers. Supernatant was obtained by
colostrum centrifugation at 160 × g for 10 min at 4 °C. The
upper fat layer was discarded, and the aqueous supernatant
was stored at −80 °C for later biochemical and immuno-
logical analyses.
Blood sampling
Samples of 10 mL of blood were collected prior to the
beginning of labor from each mother in tubes without
anticoagulant and the blood samples were centrifuged at
160 × g for 15 min, until serum separation. Serum samples
were stored individually at −80 °C for further glucose,
enzyme and protein determination.
Glucose determination
Glucose concentrations of colostrum supernatant and
maternal serum were determined by the enzymatic
system [25]. Samples of 20 μL colostrum, serum and
standard of 100 mg/dL (BioTécnica®, Ref 10.008.00, Brazil)
were placed in 2.0 mL phosphate buffer solution (0.05 M,
pH7.45, with aminoantipyrine 0.03 mM, 15 mM sodium
p-hydroxybenzoate, 12 kU/L glucose oxidase and 0.8 kU/L
peroxidase). The suspensions were mixed and incubated
for 5 min at 37 °C. The reactions were read on a spectro-
photometer at 510 nm.
Total protein determination
Total protein of colostrum supernatant and maternal
serum was determined by the Biuret colorimetric method
[25]. Samples of 20 μL of colostrum, serum and standard of
4 g/dL (BioTécnica®, Ref 10.009.00, Brazil) were placed in
1.0 mL Biuret reagent (ions of copper in alkaline medium).
The suspensions were mixed and incubated for 10 min at
37 °C. The reactions were read on a spectrophotometer at
545 nm.
Cholesterol determination
Cholesterol concentrations of colostrum supernatant
and maternal serum were determined by enzymatic
colorimetric method [26]. Samples of 10 μL colostrum/
serum and standard of 200 mg/dL BioTécnica®, Ref
10.004.00, Brazil), were placed in 1 mL of buffer solution
(100 mmol/L, pH 7.0; Sodium cholate 8 mmol/L; cho-
lesterol esterase 750 U/L; Cholesterol oxidase/200 U/L;
Peroxidase > 2000 U/L; 4-aminoantipyrine 0.6 mmol; phe-
nol 20 mmol /L; Sodium azide 0.05 % v/v). The suspensions
were mixed and incubated for 10 min at 37 °C. The
reactions were read on a spectrophotometer at 505 nm.
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Triglycerides determination
Triglycerides concentrations in colostrum supernatant and
maternal serum were determined by the enzymatic colori-
metric method [26]. Samples of 10 μL of colostrum/serum,
standard of 200 mg/dL (BioTécnica®, Ref 10.010.00,
Brazil), were placed in 1.0 mL of buffer solution
(50 mmol/L pH 7.2 Glicerol kinase/1000 U/L; Peroxidase/
1000 U/L; Lipoprotein lipase/2000 U/Ll; Glycerol-3-
phosphate oxidase/5000 U/L; 4-chlorophenol 2.7 mmol/L;
4-aminoantipyrine 0.3 mmol/L; ATP - adenosine triphos-
phate 2.0 mmol/L; Sodium azide 0.01 % v/v). The suspen-
sions were mixed and incubated for 10 min at 37 °C. The
reactions were read on a spectrophotometer at 505 nm.
Immunoglobulin, C3 and C4 complement determination
The immunoglobulin (Ig), complement protein (C) 3 and 4
concentrations in colostrum and serum were determined
by turbidimetric method [11].
For sIgA in colostrum and IgA in serum determinations,
the samples were diluted at 1:5 (v/v) with saline solution
(9 g/L), for IgM at 1:11 (v/v) and for IgG at 1:15 (v/v), and
the antibody concentrations were determined using IgA
(Bioclin®, Brazil, Ref K061), IgM (Bioclin®, Brazil, Ref
K063) and IgG antiserum (Bioclin®, Brazil, Ref K062)
diluted at 1:12 (v/v). A calibration curve obtained by the
Multical (Bioclin®, Brazil, Ref K064) calibrator was used to
determine the standard curve for each immunoglobulin.
Samples of colostrum, serum, standards, positive and nega-
tive control sera were placed in 500 μL of buffer solution
(sodium chloride 0.15 moL/L, Tris 50 mmol/L, 6.0000
PEG 50 g/L, sodium azide 15.38 nmol/L). The suspensions
were mixed and incubated at 37 °C for 10 min. The reac-
tions were read on a spectrophotometer at 340 nm.
For C3 and C4 concentration determination the samples
(colostrum and serum) were diluted at 1:12 (v/v) with
saline solution (9 g/L), and the C3 and C4 concentrations
in sample supernatants were determined using C3 and C4
antiserum (Bioclin®, Brazil) diluted at 1:12 (v/v). A calibra-
tion curve obtained by the Multical (Bioclin®, Brazil), Ref
K064) calibrator was used to determine the standard
curve. Ten microliter samples of colostrum, serum,
standards, positive and negative control sera were
placed in 500 μL of buffer solution (sodium chloride
0:15 mol/L, Tris 50 mmol/L, 6.0000 PEG 50 g/L, sodium
azide 15:38 nmol/L). The suspensions were mixed and
incubated at 37 °C for 15 min. The reactions were read on
a spectrophotometer at 340 nm.
Creamatocrit analysis
Colostrum samples were water-bath-heated at 40 °C for
15 min and subjected to vortex mixing. Capillary tubes
(2 μL) were filled to approximately three quarters with
the samples, sealed with sealing wax and centrifuged for
15 min. Centrifugation separated the samples into cream
and serum [2]. The cream column and the total column
were measured, and fat and Kcal content calculated
using the following formulae:
Fat content ¼ % cream − 0:59=1:46; where the % cream
¼ cream column mmð Þ
 100 =total column mmð Þ;
Kcal=L ¼ 68:8  % creamð Þ þ 290
C-Reactive Protein assay
C-Reactive Protein (CRP) concentrations in human
colostrum and serum were measured using the PCR
Turbilatex Kit (BioTécnica®, Brazil, Catalog 20.015.00) by
turbidimetric method [26]. Samples of 5 μL of colostrum,
serum and standard were placed in 1000 μL of solution
(phosphate Buffer 40 mmol, sodium azide 0.95 g/L,
suspension of latex particles sensitized with goat IgG anti
Human C-reactive protein). The suspensions were mixed
and placed at 37 °C and the reactions were measured
immediately and at 120 s. The reactions were read on
a spectrophotometer at 540 nm.
Statistical analysis
Two-way Analysis of variance (ANOVA) with calculation of
F statistic and Tukey’s multiple comparison test were used
to evaluate glucose, total protein, cholesterol, triglycerides,
antibody concentration, complement protein, CRP, calories
and fat considering the BMI status as one factor and the
biological materials (colostrum or serum) as the other.
Statistical significance was considered when the p-value was
less than .05.
Results
Clinical characteristics from all groups are shown in
Table 1. Maternal age, gestational age at birth and height
before pregnancy were similar among groups. The
cesarean birth percentage was higher in overweight
and obese groups. Neonates from the groups studied
(normal weight, overweight and obese) exhibited similar
somatometry at birth (Table 1).
We evaluated biochemical (Table 2) and immunological
(Table 3) parameters in the blood and colostrum of
mothers with different body mass index (BMI).
Colostrum glucose concentrations were higher in obese
(p = .002) than in overweight and normal weight groups.
Serum glucose concentrations were higher (p = .001) than
colostrum glucose concentrations in overweight mothers
(Table 2). Total protein concentrations were similar
(p = .758) across the groups. In normal weight and obese
groups, total protein concentrations were higher in colos-
trum (p = .001) than in maternal serum (Table 2).
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Intergroup colostrum triglyceride concentrations
were similar, but in serum they were significantly higher
(p = .008) in the obese group. Irrespective of the BMI,
triglyceride concentrations were higher (p = .001) in
colostrum than in serum (Table 2). No statistical intergroup
differences (p > 0.05) in cholesterol concentrations were
detected in colostrum. However, obese women exhibited
higher cholesterol concentrations in serum (p = .010) than
normal weight individuals. In the obese group, cholesterol
concentrations were higher in serum (p = .001) than
in colostrum (Table 2).
As shown in Fig. 1 and Table 2, fat (p = .005) and calorie
(p = .003) content of colostrum was higher in the obese
group. Colostrum CRP concentrations were similar among
Table 2 Biochemical parameters in colostrum and serum from normal weight, overweight and obese mothers
Parameter Normal weight Overweight Obese Statistical
Glucose concentrations
(mmol/L)
Colostrum 1.9 (0.7–2.9) 3 2.6 (2.1–3.1) 1,3 3.2 (2.0–4.5) 1,2,3 F = 5.94; p = .002 (comparing the groups)
Serum 4.3 (4.2–5.1) 4.4 (3.7–5.4) 4.3 (3.7–5.7) F = 139.15; p = .001 (comparing the
colostrum and serum)
Total Protein (g/L) Colostrum 101.0 (91.0–115.0) 3 89.0 (76.0–127.0) 86.0 (61.0–157.0) 3 F = 0.25; p = .758 (comparing the groups)
Serum 59.0 (57.0–67.0) 62.5 (58.0–83.0) 66.5 (54.0–76.0) F = 47.53; p = .001 (comparing the
colostrum and serum)
Triglyceride concentrations
(mmol/L)
Colostrum 5.3 (2.5–6.6) 3 5.1 (2.5–6.3) 3 4.6 (2.6–8.0) 3 F = 10.59; p = .008 (comparing the groups)
Serum 1.6 (0.8–2.2) 1.9 (0.9–3.3) 2.9 (2.0–5.5) 1 F = 57.47; p = .001 (comparing the
colostrum and serum)
Cholesterol concentrations
(mmol/L)
Colostrum 4.3 (2.1–6.2) 4.1 (2.7–5.9) 5.2 (2.9–8.2) 3 F = 5.05; p = .010 (comparing the groups)
Serum 5.1 (4.7–5.4) 5.4 (4.6–5.9) 6.0 (5.2–12.3) 1 F = 11.08; p = .002 (comparing the
colostrum and serum)
CRP concentrations (mg/L) Colostrum 4.0 (0.0–8.0) 5.0 (0.0–11.0) 6.0 (0.0–12.0) F = 12.30; p = .002 (comparing the groups)
Serum 9.0 (5.0–28.0) 16.0 (0.0–26.0) 3 85.0 (17.0–201.0) 1,2,3 F = 20.71; p = .001 (comparing the
colostrum and serum)
Fat (%) Colostrum 3.3 (0.4–6.7) 3.6 (1.2–9.4) 5.6 (2.0–11.9) 1 F = 7.27; p = .005 (comparing the groups)
Calories (Kcal) Colostrum 537.9 (396.7–764.3) 543.6 (396.7–944.6) 688.2 (450.3–1111.6) 1 F = 6.90; p = .003 (comparing the groups)
Data presented as media, minimum and maximum values
1Statistically significant differences in relation to the normal weight category, considering the same sample (colostrum or serum)
2Statistically significant differences in relation to the overweight category, considering the same sample (colostrum or serum)
3Statistically significant differences between colostrum and serum, considering the same group (normal weight, overweight and obese)
Table 1 Clinical characteristics of woman included in the study according to pregestacional BMI group (normal, overweight and obese)
Variables Normal weight (n = 25) Overweight (n = 24) Obese (n = 18)
Mothers
Age (year) 25.0 (18–37) 24.1 (18–37) 26.8 (21–38)
height before pregnancy (cm) 161.0 (150.0-171.0) 162.8 (150.0-172.0) 160.4 (144.0-189.0)
Weight before pregnancy (kg) 56.2 (43.0-68.5) 71.2 (56.5-82.0) 87.3 (66.0-110.0)
BMI before pregnancy (kg/m2) 21.4 (18.4-24.4) 26.6 (25.2-28.6) 34.7 (30.1-47.9)
Cesarean (%) 6/25 (24.0 %) 11/24 (45.8 %) 10/18 (55.5 %)
Gestational age at delivery (week) 39.7 (37.0-41.3) 39.5 (37.6-41.0) 39.5 (37.0-40.7)
Primipara (%) 13/25 (52.0 %) 11/24 (45.8 %) 8/18 (44.4 %)
Diabetes 0/25 (0.0 %) 0/24 (0.0 %) 0/18 (0.0 %)
Gestational diabetes 0/25 (0.0 %) 0/24 (0.0 %) 2/18 (11.0 %)
Hypertension 1/25 (4.0 %) 1/24 (4.0 %) 2/18 (11.0 %)
Smoking status 4/25 (16.0 %) 2/24 (8.0 %) 2/18 (11.0 %)
Infants
Infant gender (% female) 12/25 (48.8 %) 10/24 (41.6 %) 8/18 (44.4 %)
Weight (kg) 3.6 (2.40-4.20) 3.2 (2.54-3.91) 3.4 (2.54-4.34)
Height (cm) 48.1 (44.0-52.0) 48.2 (44.5-53.0) 49.2 (46–52)
Data for all mothers included are shown as median, minimum and maximum values or number and percentages (%)
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the groups, but in serum, they were significantly higher in
the obese group (p = .002) than in the other groups. The
highest concentrations of CRP (p = .001) were found in
serum (Fig. 2 and Table 2).
The obese group showed significantly higher (p = .001)
colostrum sIgA and serum IgA concentrations than
normal weight women. IgM concentrations did not
vary (p = .825) among the groups and between serum
and colostrum samples (p = .177). IgG concentrations
were significantly higher in serum (p = .001) than in
colostrum (Table 3).
In serum, the concentrations of complement proteins
C3 (p = .001) and C4 (p = .040) were significantly higher
(p = .010) in the obese group than in normal weight and
overweight groups, but in colostrum did not differ among
the groups. Irrespective of weight status, C3 concentra-
tions were significantly higher in serum (p = .001) than in
colostrum, and in normal weight and overweight groups,
C4 concentrations were significantly higher in serum
(p = .001) than in colostrum samples (Table 3).
Discussion
The immune protection that breast milk provides and its
nutritional importance has been widely described, and
the composition of this secretion is known to undergo
inter-and intra-individual variations [27]. These variations
in breast milk can be affected by several factors, such as
maternal diet, nutritional status, smoking, parity and
period of the day [2, 28, 29].
Other studies report that maternal anemia, hypertension
and diabetes can change nutritional and immunological
features of breast milk [11, 30–32]. The present study
shows that although serum cholesterol, triglycerides, CRP,
C3 and C4 protein concentrations were higher in obese
women, their concentrations in colostrum were similar
across the groups. On the other hand, although glucose
and IgA concentrations were similar among serum
samples of the different groups, in colostrum samples
sIgA concentrations were significantly higher in obese
mothers. An increase in glucose concentrations in
the breast milk of diabetic women are associated with
Table 3 Immunoglobulins and complement protein concentrations in colostrum and serum from normal weight, overweight and
obese mothers
Parameter Normal weight Overweight Obese Statistical
IgA (g/L) Colostrum 3.3 (2.3-5.5) 3 3.8 (2.1-5.0) 5.1 (3.3-9.6) 1,2,3 F = 12.44; p = .001 (comparing the groups)
Serum 2.2 (1.6-3.1) 2.7 (2.2-3.5) 3.9 (2.1-4.7) 1 F = 21.69; p = .002 (comparing the colostrum and serum)
IgM (g/L) Colostrum 1.3 (0.85-2.2) 1.2 (0.8-2.1) 1.4 (1.0-3.4) F = 0.19; p = .825 (comparing the groups)
Serum 1.3 (1.1-1.8) 1.4 (0.8-2.4) 1.0 (0.8-2.0) F = 1.84; p = .177 (comparing the colostrum and serum)
IgG (g/L) Colostrum 0.4 (0.1-0.6) 3 0.3 (0.2-0.5) 3 0.4 (0.2-0.6) 3 F = 0.05; p = .947 (comparing the groups)
Serum 11.3 (9.2-14.2) 9.3 (8.5-16.7) 10.8 (7.6-18.4) F = 495.8; p = .001 (comparing the colostrum and serum)
C3 (mg/dL) Colostrum 91.7 (50.5-110.2) 3 90.3 (44.1-97.9) 3 95.7 (41.3-130.9) 3 F = 14.98; p = .001 (comparing the groups)
Serum 121.1 (109.5-139.3) 152.4 (90.6-250.0) 249.8 (119.1-312.9) 1,2 F = 117.30; p = .001 (comparing the colostrum and serum)
C4 (mg/dL) Colostrum 30.1 (15.6-34.8) 3 24.2 (19.6-40.7) 3 28.8 (17.7-40.2) F = 5.91; p = .040 (comparing the groups)
Serum 16.4 (9.9-25.6) 17.2 (7.1-25.8) 22.9 (13.3-37.1) 1,2 F = 20.68; p = .001 (comparing the colostrum and serum)
Data presented as median, minimum and maximum values (within parentheses)
1Statistically significant differences in relation to the normal weight category, considering the same sample (colostrum or blood)
2Statistically significant differences in relation to the overweight category, considering the same sample (colostrum or blood)
3Statistically significant differences between colostrum and serum, considering the same group (normal weight, overweight and obese)
Fig. 1 Fat a and calories b in the colostrum of normal, overweight and obese mothers. Data presented as mean ± standard error (SE). F(A) = 7.27;
p = .005; F(B) = 6.90; p = .003. *Statistically significant differences between normal and obese groups. †Statistically significant differences between
overweight and obese groups
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long-term consequences for their children, such as an
increase in weight gain and metabolic changes [33, 34].
This suggests that infants born to and breastfed by
women with high prepregnancy BMI may be heavier
and predisposed to develop obesity and related disor-
ders in adulthood. Other studies should investigate
the effects of maternal weight on the glucose content
of breast milk and its impact on infant weight gain
and metabolism.
The association between maternal obesity and dyslipid-
emia has been extensively described [35–37], and it likely
contributes to vascular diseases including preeclampsia and
the development of macrosomia [38]. The present study
also found increased of dyslipidemia markers in higher
BMI groups in colostrum samples, given that in obese and
overweight groups this secretion contained higher fat and
calorie content compared to normal weight women. The
effects of maternal BMI on the energy content of breast
milk are controversial, with studies showing that fat content
in the milk of obese women does not differ from that of
other weight classes [39], whereas others report lower fat
content in milk from overweight mothers [28].
The immaturity of the immune system of newborns
makes it susceptible to infections by viruses and bacteria.
Accordingly, the transfer of antibodies via placenta during
uterine life and then via colostrum and breast milk after
birth is important in reducing this deficiency [30]. In the
present study, overweight and obese mothers exhibited
higher IgA concentrations in serum and sIgA concentra-
tions in colostrum than normal weight women. Earlier
studies report that obesity increases serum IgA concentra-
tions in both sexes [40]. The present study is the first to
evaluate the concentrations of antibodies and complement
proteins in colostrum of overweight pregnant women.
The increase in sIgA concentrations in colostrum might
be associated with conditions determined by the metabolic
syndrome, including hyperglycemia, hypertriglyceridemia
and abdominal obesity. The mechanisms by which obesity
increases sIgA concentrations are not known, but they are
possibly associated with chronic low-grade inflammation,
characterized by elevated concentrations of serum
pro-inflammatory marker IL-6 [40]. IL-6 is one of the
main cytokines in human milk, and its content has
been shown to correlate with sIgA concentrations in
colostrum in other studies [41, 42].
Unlike IgG, which is transferred transplacentally, the
action of immunoprotective components of colostrum and
milk is usually local, in the newborn’s intestinal mucosa [3].
sIgA is able to inhibit bacterial adhesion and neutralize
virus infection in the intestinal mucosa, preventing
tissue damage and loss of energy [43] through a non-
inflammatory process called immune exclusion [44]. The
IgG antibodies activate the complement system and
granulocytes and induce cytokine production, which results
in inflammation. sIgA can also act as opsonin, signal-
ing the presence of antigens to phagocytes by binding
to the surface of bacteria and facilitating aggregation.
The opsonizing activity of sIgA is of great biological
significance, and given that colostrum is the secretion
containing the highest concentration of this antibody
class, it provides a complete micro-environment where
components found in both its soluble portion and cells act
together [3, 44].
The increased serum C3 concentrations in overweight
and obese women and serum C4 in the obese group was
not accompanied by an increase in these concentrations
in colostrum. It was previously reported that obese indi-
viduals exhibit higher concentrations of circulating C3
[45, 46] and C4 [47]. The complement system consists
of proteins that interact to provide many of the effector
functions of humoral immunity and inflammation [45].
C3 and C4, the central components of the complement
pathway of the immune system, are synthesized by stimula-
tion of pro-inflammatory cytokines [46]. The C3 and C4
proteins are mainly produced in the liver, but they can also
be synthesized and expressed in other tissues such as the
adipose [47]. It has been suggested that diagnosis of chronic
low-grade inflammation, which characterizes obesity, is
Fig. 2 CRP concentrations in the colostrum a and serum b of normal, overweight and obese mothers. Data presented as mean ± standard error
(SE). F = 12.30; p = .002 comparing the groups; F = 20.71; p = .001 comparing the samples (colostrum and serum). * Statistically significant differences
between normal and obese groups. †Statistically significant differences between overweight and obese groups
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responsible for activation of the complement system, which,
in turn, would cause the associated metabolic complica-
tions [48].
Obese mothers exhibited higher concentrations of serum
CRP, but not in colostrum. CRP secretion by the liver is
stimulated by several inflammatory cytokines, which
are released in response to trauma, infection and
inflammation, and this protein rapidly reduces the reso-
lution of these conditions [49]. Another study found an
association between serum CRP concentrations and
prepregnancy BMI [50]. High CRP concentrations in
the amniotic fluid of obese mothers expose the fetus
to high amounts of inflammatory mediators, which may
contribute to fetal programming, account for various
complications during pregnancy and impact health
condition in adulthood [51].
It should be considered that these data were evaluated
in one period of collection and only one milk maturation
stage that may be considered a limitation of this study.
It is necessary to continue investigations focusing on
other factors that may be involved during breastfeeding
of the mothers with BMI alterations.
Conclusions
The data obtained in the present study support the
hypothesis that metabolic changes promoted by obesity
can change the biochemical and immunological parame-
ters of breast milk. Nevertheless, we did not observe any
changes that could cast doubt on the protection that
breastfeeding provides to newborns or that could reflect
the inflammatory state observed in maternal serum,
because the only immunological component that in-
creased in serum the obese women was IgA, which is
known to be a non-inflammatory antibody. However,
the increased calorie and fat content and glucose con-
centrations detected in colostrum from obese women
deserve further attention.
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